Can I Take Lipitor and Pain Relievers Before Bedtime? A Comprehensive Guide Taking medications before bedtime can be a common… https://www.Drugchatter.com/chat/21744/can-i-take-lipitor-and-pain-relievers-before-bedtime/
DrugChatter: Can i take lipitor and pain relievers before bedtime? Read Post »
Generic entry is inevitable—unless you build a moat that can’t be copied.
In pharma, we obsess over patents on molecules, formulations, and brand names. But the most durable defense against generic competition often lives in a less glamorous place: p…
Biotech IPOs can look like rocket fuel—until the patent due diligence catches fire.
If you’re an investor, founder, or advisor, you already know the headline risks: clinical timelines, trial design, manufacturing scale-up, reimbursement. But there’s a …
Don’t Get Burned: 3 Critical Patent Due Diligence Steps Before Investing in Biotech IPOs Read Post »
Biosimilar entry windows aren’t just math—they’re strategy under uncertainty.
Most teams treat the “entry window” like a spreadsheet problem: map patents, estimate exclusivity, model launch dates, and move on. But the companies that win in biosimilar…
5 Costly Mistakes Companies Make When Modeling Biosimilar Entry Windows Read Post »
Generic and biosimilar development is a high-stakes game of timing, risk, and capital allocation. Yet many teams still make go/no-go decisions with incomplete visibility—treating patent landscapes as a compliance checkbox instead of a strategic decisio…
Designing Around the Moat: Why Secondary Formulation Patents Are the New Battleground for Generic Developers
Generic drug development has always been a game of precision—timelines, regulatory strategy, and patent analytics all matter. But in today’s pa…
Designing Around the Moat: A Generic Developer’s Guide to Secondary Formulation Patents Read Post »
Pharma doesn’t just “own” a drug patent—it often extends control over time.
That’s the core tension behind the industry’s playbook for maximizing value from patent term extensions and secondary patents. In a world where blockbuster revenue is measured …
Your pharmaceutical portfolio may have a time bomb in it—and patent expiration data is the fuse.
If you’re a business leader in pharma, you already know the headline risk: patents expire, generics arrive, margins compress, and growth plans get rewritte…
The Hidden Dangers of Combining Lipitor with Salt Substitutes As we age, our bodies undergo a multitude of changes that… https://www.Drugchatter.com/chat/38920/are-there-any-dangers-in-using-lipitor-alongside-salt-substitutes/
DrugChatter: Are there any dangers in using lipitor alongside salt substitutes? Read Post »
Big Pharma loves a good wall.
Not the kind you can scale with grit and a ladder—but the kind built from patents, procedural delays, and “trust us” narratives. In the pharmaceutical world, IP strategy can feel like a fortress: opaque, expensive to chall…
Crack the Patent Wall: How Hard Data Beats Big Pharma’s IP Strategy Every Time Read Post »
Get new actionable insights and updates from BiotechBlog
